Middle East & Africa Cell Therapy Market Size & Outlook
Middle East & Africa cell therapy market, 2018-2030 (US$M)
Related Markets
MEA cell therapy market highlights
- The MEA cell therapy market generated a revenue of USD 69.7 million in 2023.
- The market is expected to grow at a CAGR of 14.3% from 2024 to 2030.
- In terms of segment, autologous therapies was the largest revenue generating therapy type in 2023.
- Allogeneic Therapies is the most lucrative therapy type segment registering the fastest growth during the forecast period.
MEA data book summary
| Market revenue in 2023 | USD 69.7 million |
| Market revenue in 2030 | USD 177.8 million |
| Growth rate | 14.3% (CAGR from 2023 to 2030) |
| Largest segment | Autologous therapies |
| Fastest growing segment | Allogeneic Therapies |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Allogeneic Therapies, Autologous Therapies |
| Key market players worldwide | Novartis AG ADR, Gilead Sciences Inc, Bristol-Myers Squibb Co, Johnson & Johnson, JCR Pharmaceuticals Co Ltd, JW (Cayman) Therapeutics Co Ltd Ordinary Shares, Atara Biotherapeutics Inc, Medipost, Beiersdorf AG, Nkarta Inc Ordinary Shares |
Other key industry trends
- In terms of revenue, MEA region accounted for 1.5% of the global cell therapy market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Europe is the fastest growing regional market and is projected to reach USD 6,066.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell Therapy Market Scope
Cell Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Middle East & Africa cell therapy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell therapy market will help companies and investors design strategic landscapes.
Autologous therapies was the largest segment with a revenue share of 99.28% in 2023. Horizon Databook has segmented the Middle East & Africa cell therapy market based on allogeneic therapies, autologous therapies covering the revenue growth of each sub-segment from 2018 to 2030.
- Middle East & Africa Cell Therapy Therapy Type Outlook (Revenue, USD Million, 2018-2030)
- Allogeneic Therapies
- Stem Cell Therapies
- Hematopoietic Stem Cell Therapies
- Mesenchymal Stem Cell Therapies
- Non-stem Cell Therapies
- Keratinocytes & Fibroblast-based Therapies
- Others
- Stem Cell Therapies
- Autologous Therapies
- Stem Cell Therapies
- BM, Blood, & Umbilical Cord-derived Stem Cells
- Adipose Derived Cells
- Others
- Non-stem Cell Therapies
- T-Cell Therapies
- CAR T Cell Therapy
- T Cell Receptor (TCR)-based
- Others
- T-Cell Therapies
- Stem Cell Therapies
- Allogeneic Therapies
- Middle East & Africa Cell Therapy Therapeutic Area Outlook (Revenue, USD Million, 2018-2030)
- Oncology
- Cardiovascular Disease (CVD)
- Musculoskeletal Disorders
- Dermatology
- Others
Reasons to subscribe to Middle East & Africa cell therapy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa cell therapy market databook
-
Our clientele includes a mix of cell therapy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa cell therapy market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa cell therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Middle East & Africa cell therapy market
Middle East & Africa Cell Therapy Market Outlook Share, 2023 & 2030 (US$M)
Middle East & Africa cell therapy market
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
